| Item Type | Name |
|
Concept
|
Methylprednisolone
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Muscle Neoplasms
|
|
Concept
|
Dexamethasone
|
|
Concept
|
DNA Methylation
|
|
Concept
|
Electronic Health Records
|
|
Concept
|
Ki-67 Antigen
|
|
Concept
|
Necrosis
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Brain Diseases, Metabolic, Inborn
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
Occupational Therapy
|
|
Concept
|
Lung Neoplasms
|
|
Concept
|
Cyclin-Dependent Kinase 6
|
|
Concept
|
Myasthenia Gravis
|
|
Concept
|
Kaplan-Meier Estimate
|
|
Concept
|
Lead
|
|
Concept
|
Gliosarcoma
|
|
Concept
|
Humans
|
|
Concept
|
Lymphoma, Non-Hodgkin
|
|
Concept
|
Incidence
|
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Texas
|
|
Concept
|
Leukemia, B-Cell
|
|
Concept
|
Magnetic Resonance Imaging
|
|
Concept
|
DNA Repair Enzymes
|
|
Concept
|
Lanosterol
|
|
Concept
|
Meningitis, Cryptococcal
|
|
Concept
|
Spinal Cord Neoplasms
|
|
Concept
|
Patient Care Team
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Disease Progression
|
|
Concept
|
Cerebral Ventricle Neoplasms
|
|
Concept
|
Ganglioglioma
|
|
Concept
|
Neoplasms, Neuroepithelial
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Sarcoma
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Cytarabine
|
|
Concept
|
Neurofibromatosis 1
|
|
Concept
|
Multiple Sclerosis, Relapsing-Remitting
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Mediator Complex
|
|
Concept
|
Lomustine
|
|
Concept
|
Animals
|
|
Concept
|
Glial Fibrillary Acidic Protein
|
|
Concept
|
Antigens, Neoplasm
|
|
Concept
|
DNA Modification Methylases
|
|
Concept
|
Neuroma, Acoustic
|
|
Concept
|
Lead Poisoning
|
|
Concept
|
Disease-Free Survival
|
|
Concept
|
Pituitary Neoplasms
|
|
Concept
|
Hydroxamic Acids
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Subacute Combined Degeneration
|
|
Concept
|
Leukemia
|
|
Concept
|
Blotting, Western
|
|
Concept
|
Lymphoma
|
|
Concept
|
Injections, Spinal
|
|
Concept
|
Bone Neoplasms
|
|
Concept
|
Oligodendroglioma
|
|
Concept
|
Neuroprotective Agents
|
|
Concept
|
DNA (Cytosine-5-)-Methyltransferases
|
|
Concept
|
Neurofibromin 1
|
|
Concept
|
Hyaluronan Receptors
|
|
Concept
|
Glioma
|
|
Concept
|
Biopsy
|
|
Concept
|
Radiation Injuries
|
|
Concept
|
Adenoma
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Cytosine Deaminase
|
|
Concept
|
Smad Proteins
|
|
Concept
|
Caspase 3
|
|
Concept
|
Meningioma
|
|
Concept
|
Galectin 3
|
|
Concept
|
Mice
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Cyclin-Dependent Kinase 4
|
|
Concept
|
Immunoenzyme Techniques
|
|
Concept
|
Waldenstrom Macroglobulinemia
|
|
Concept
|
Germ-Line Mutation
|
|
Concept
|
Histone Deacetylases
|
|
Concept
|
Astrocytoma
|
|
Concept
|
Middle Cerebral Artery
|
|
Concept
|
Matrix Metalloproteinase 9
|
|
Concept
|
Olivary Nucleus
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Seizures
|
|
Concept
|
Methotrexate
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Neural Cell Adhesion Molecule L1
|
|
Concept
|
Liver Neoplasms
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Tissue Preservation
|
|
Concept
|
Quality of Life
|
|
Concept
|
Chromosomes, Human, Pair 22
|
|
Concept
|
Receptor-Interacting Protein Serine-Threonine Kinases
|
|
Concept
|
Xenograft Model Antitumor Assays
|
|
Concept
|
Severity of Illness Index
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Pilot Projects
|
|
Concept
|
Anaplasia
|
|
Concept
|
Cancer Care Facilities
|
|
Concept
|
Neuroendocrine Tumors
|
|
Concept
|
Supratentorial Neoplasms
|
|
Concept
|
Central Nervous System Neoplasms
|
|
Concept
|
Longitudinal Studies
|
|
Concept
|
Fatal Outcome
|
|
Concept
|
Caspases
|
|
Concept
|
Aminopyridines
|
|
Concept
|
Survival Analysis
|
|
Concept
|
Coculture Techniques
|
|
Concept
|
Prednisone
|
|
Concept
|
Memory
|
|
Concept
|
Histone Deacetylase Inhibitors
|
|
Concept
|
Diffusion Magnetic Resonance Imaging
|
|
Concept
|
Meningeal Neoplasms
|
|
Concept
|
Chromosomes, Human, Pair 19
|
|
Concept
|
Myelin Basic Protein
|
|
Concept
|
Lymph Nodes
|
|
Concept
|
Mice, SCID
|
|
Concept
|
Prevalence
|
|
Concept
|
Muscular Atrophy, Spinal
|
|
Concept
|
Neurofibromatosis 2
|
|
Concept
|
Reproducibility of Results
|
|
Concept
|
Gamma Rays
|
|
Concept
|
Neoplasms, Radiation-Induced
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Status Epilepticus
|
|
Concept
|
Rats
|
|
Concept
|
Randomized Controlled Trials as Topic
|
|
Concept
|
Benzamides
|
|
Concept
|
Neurofibromin 2
|
|
Concept
|
Wnt2 Protein
|
|
Concept
|
Muscle Weakness
|
|
Concept
|
Receptors, Fibroblast Growth Factor
|
|
Concept
|
Rats, Sprague-Dawley
|
|
Concept
|
Rosette Formation
|
|
Concept
|
Ependymoma
|
|
Concept
|
Risk Factors
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Benzhydryl Compounds
|
|
Concept
|
Phosphatidylinositol 3-Kinases
|
|
Concept
|
Azacitidine
|
|
Concept
|
Fourth Ventricle
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Gene Knockdown Techniques
|
|
Concept
|
Glioblastoma
|
|
Academic Article
|
Corrigendum to 'Ependymomas arising outside of the central nervous system: A case series and literature review' [J Clin Neurosci 47 (2018) 202-207].
|
|
Academic Article
|
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.
|
|
Academic Article
|
Child Neurology: cognitive delay in a 7-year-old girl.
|
|
Academic Article
|
The molecular landscape of glioma in patients with Neurofibromatosis 1.
|
|
Academic Article
|
Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution.
|
|
Academic Article
|
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
|
|
Academic Article
|
Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth.
|
|
Academic Article
|
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
|
|
Academic Article
|
MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
|
|
Concept
|
Natalizumab
|
|
Concept
|
Bevacizumab
|
|
Concept
|
Everolimus
|
|
Concept
|
Rituximab
|
|
Concept
|
Protein Domains
|
|
Concept
|
G1 Phase Cell Cycle Checkpoints
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Wakefulness-Promoting Agents
|
|
Concept
|
ErbB Receptors
|
|
Concept
|
Transcranial Direct Current Stimulation
|